Biologic therapy for systemic sclerosis: A systematic review

Journal of Rheumatology

Volumn 38, Issue 2, 2011, Pages 289-296

  Phumethum, Veerapong ^a,b   Jamal, Shahin ^c   Johnson, Sindhu R ^a,d,e  

^a MOUNT SINAI HOSPITAL   (Canada)

^b PRAPOKKLAO HOSPITAL   (Thailand)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti tumor necrosis factor ; Biologic; Scleroderma; Systemic sclerosis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA INTERFERON; COLLAGEN TYPE 1; ETANERCEPT; GAMMA INTERFERON; IMATINIB; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RELAXIN; RITUXIMAB; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA 1 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTHRITIS; BIOLOGICAL THERAPY; DEATH; DISABILITY; DRUG HYPERSENSITIVITY; FEVER; FLU LIKE SYNDROME; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; ISCHEMIA; LUPUS LIKE SYNDROME; MENORRHAGIA; MYALGIA; MYCOBACTERIUM VACCAE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SCORING SYSTEM; SERUM SICKNESS; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; URTICARIA;

ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; HUMANS; IMMUNOGLOBULIN G; INTERFERON-ALPHA; PIPERAZINES; PYRIMIDINES; RECEPTORS, TUMOR NECROSIS FACTOR; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551704329     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100361     Document Type: Review

References (53)

1. Misra R, Darton K, Jewkes RF, Black CM, Maini RN. Arthritis in scleroderma. Br J Rheumatol 1995;34:831-7.
2. La Montagna G, Baruffo A, Tirri R, Buono G, Valentini G. Foot involvement in systemic sclerosis: a longitudinal study of 100 patients. Semin Arthritis Rheum 2002;31:248-55. (Pubitemid 34160808)
3. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. J Rheumatol 2010;37:1488-501.
4. Schumacher HR Jr. Joint involvement in progressive systemic sclerosis (scleroderma): a light and electron microscopic study of synovial membrane and fluid. Am J Clin Pathol 1973;60:593-600.
5. Low AH, Lax M, Johnson SR, Lee P. Magnetic resonance imaging of the hand in systemic sclerosis. J Rheumatol 2009;36:961-4.
6. Morita Y, Muro Y, Sugiura K, Tomita Y. Anti-cyclic citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol 2008;26:542-7.
7. Marrone M, Chiala A, Tampoia M, Iannone F, Raho L, Covelli M, et al. [Prevalence of anti-CCP antibodies in systemic sclerosis]. Reumatismo 2007;59:20-4.
8. Distler JH, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 2008;58:2228-35.
9. Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990;344:245-7. (Pubitemid 20094924)
10. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994;7:515-8. (Pubitemid 24099014)
11. Liu JY, Brass DM, Hoyle GW, Brody AR. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998;153:1839-47.
12. Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998;24:721-43. (Pubitemid 28533206)
13. Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks WA, et al. Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999;20:825-33.
14. Mauviel A, Daireaux M, Redini F, Galera P, Loyau G, Pujol JP. Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett 1988;236:47-52.
15. Mauviel A, Heino J, Kahari VM, Hartmann DJ, Loyau G, Pujol JP, et al. Comparative effects of interleukin-1 and tumor necrosis factor-alpha on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts. J Invest Dermatol 1991;96:243-9.
16. Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990;269:93-5. (Pubitemid 20245325)
17. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8. (Pubitemid 16149701)
18. Meikle MC, Atkinson SJ, Ward RV, Murphy G, Reynolds JJ. Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res 1989;24:207-13.
19. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF-alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004;63 Suppl 2:ii2-12.
20. Keyser FD, Mielants H, Veys EM. Current use of biologicals for the treatment of spondyloarthropathies. Exp Opin Pharmacother 2001;2:85-93. (Pubitemid 32427716)
21. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
22. Allanore Y, Devos-Francois G, Caramella C, Boumier P, Jounieaux V, Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006;65:834-5.
23. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004;329:1266.
24. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80. (Pubitemid 34178442)
25. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408. (Pubitemid 46067817)
26. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34:1636-7. (Pubitemid 47068007)
27. Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005;143:918-20. (Pubitemid 46202235)
28. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009;68:1433-9.
29. Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: A pilot study [abstract]. Arthritis Rheum 2000;43 Suppl:S392.
30. Matteson EL, Shbeeb MI, McCarthy TG, Calamia KT, Mertz LE, Goronzy JJ. Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum 1996;39:1132-7.
31. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001;40:84-8. (Pubitemid 32124052)
32. Balaban EP, Zashin SJ, Geppert TD, Lipsky PE, Condie RM. Treatment of systemic sclerosis with antithymocyte globulin. Arthritis Rheum 1991;34:244-5.
33. van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008;58:2549-52.
34. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology 2008;47:735-7.
35. Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009;60:584-91.
36. Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B, Jabkowski J, MacHeiner W, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998;139:639-48.
37. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:299-305.
38. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871-9.
39. Genovese MC, Chakravarty EF, Boyle DL, Tutuncu Z, Thorburn CM, Halilhodzic M, et al. A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. J Rheumatol 2005;32:2345-50.
40. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti-transforming growth factor beta-1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.
41. Postlethwaite AE, Wong WK, Clements PJ, Chatterjee S, Fessler BJ, Kang AH, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008;58:1810-22.
42. Caliri A, Sangari D, Sferrazza P, Bagnato G, Bagnato G. Effectiveness of rituximab in the treatment of a rare overlap syndrome - rheumatoid arthritis/s. Sjogren/systemic sclerosis - complicated by monoclonal gammopathy [Italian]. Trends Med 2009;9:161-2.
43. McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008;47:552-3.
44. Ketari JS, Zaghdoudi I, Ben Dhaou B, Kochbati S, Mir K, Ben Ali Z, et al. [Catastrophic antiphospholipid syndrome and rituximab: a new report]. Tunis Med 2009;87:699-702.
45. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010;69:193-7.
46. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010;49:271-80.
47. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578-83.
48. Marie I, Lahaxe L, Levesque H, Heliot P. Pulmonary actinomycosis in a patient with diffuse systemic sclerosis treated with infliximab. QJM 2008;101:419-21. (Pubitemid 351619253)
49. Johnson SR, Glaman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006;33:1117-22. (Pubitemid 43825462)
50. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408.
51. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
52. Johnson SR, Hawker GA, Davis AM. The Health Assessment Questionnaire Disability Index and Scleroderma Health Assessment Questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Rheum 2005;53:256-62.
53. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009;36:2356-61.